Two phase II trials of once-daily concizumab injections for bleeding prophylaxis do not disappoint, with the drug shown to be both safe and effective in haemophilia A (HA) and haemophilia A/B with inhibitors (HAwI/HBwI).
The bi-specific T-cell engaging antibody blinatumomab bested chemotherapy as a post-reinduction consolidation prior to transplant in children and adolescents and young adults (AYAs) with first-relapse B-cell acute lymphoblastic leukaemia (B-ALL), according to phase III data presented at ASH 2019, highlighting the potential of blinatumomab as a new standard of care in this setting.
Acalabrutinib, when combined with obinutuzumab or used as monotherapy, significantly improves progression-free survival (PFS) by 80–90 percent vs chemoimmunotherapy in patients with previously-untreated chronic lymphocytic leukaemia (CLL), results of the phase III ELEVATE TN trial have shown.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.